Principal Investigator
Estelamari Rodriguez
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230512
Clinical Trial Summary
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647